FASD Prevention R33 (R33)
14 septembre 2026 mis à jour par: Yukiko Washio, Philadelphia College of Osteopathic Medicine
Adapting and Testing Behavioral Intervention to Prevent Fetal Alcohol Spectrum Disorders and Adverse Infant Outcomes (R33)
This R33 application proposes to adapt and test an evidence-based behavioral intervention to decrease polysubstance use (i.e., alcohol and tobacco/cannabis) during pregnancy and lactation and prevent adverse clinical outcomes, including fetal alcohol spectrum disorder (FASD) in South Africa (SA).
SA has a long history of social and health disparities, resulting in the world's highest rate of FASD (111.1 per 1,000), where lifelong negative cognitive and physical effects result from prenatal alcohol exposure.
FASD is completely preventable if women do not drink during pregnancy.
Prenatal alcohol use frequently co-occurs with other substance use, especially tobacco and cannabis.
The adverse effect on birth outcomes by alcohol and tobacco use together is worse than either substance alone.
Recent evidence from animal models shows that prenatal exposure to both cannabinoids and alcohol potentiate the likelihood of alcohol-induced birth defects.
Data from Cape Metropole, SA, showed that all women who reported prenatal alcohol use also tested positive for tobacco use, with 25% also reporting cannabis use.
Alcohol use while breastfeeding also occurs at a relatively high rate in SA.
Despite tremendous health benefits from breastfeeding, maternal alcohol use while breastfeeding significantly compromises infant development.
Contingency management (CM) has been efficacious in reducing prenatal cocaine, alcohol, and tobacco use in the United States (U.S.).
The Women's Health CoOp (WHC) is an evidence-based brief intervention addressing women-focused syndemic issues and resulting disparities associated with substance and alcohol use.
These evidence-based interventions need to be combined and adapted for addressing maternal polysubstance use and associated health and behavioral issues during pregnancy and lactation in SA.
Aperçu de l'étude
Statut
Pas encore de recrutement
Les conditions
Intervention / Traitement
Type d'étude
Interventionnel
Inscription (Estimé)
184
Phase
- Phase 2
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Coordonnées de l'étude
- Nom: Yukiko Washio, PhD
- Numéro de téléphone: (215) 871-6100
- E-mail: yukikowa@pcom.edu
Lieux d'étude
-
-
-
Cape Town, Afrique du Sud
- University of Cape Town
-
Contact:
- Heather Jaspan, MD, PhD
- Numéro de téléphone: +27 21 650 9111
- E-mail: hbjaspan@gmail.com
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Non
La description
Inclusion Criteria:
- (1) be pregnant, (2) intend to breastfeed, (3) test positive for alcohol use by urinalysis (i.e., EtG), (4) test positive for tobacco or cannabis use by urinalysis (i.e., cotinine and THC), (5) have an independent access to a mobile phone, (6) plan to remain in the area during pregnancy and 3 months postpartum.
Exclusion Criteria:
- Report serious medical problems threatening their current pregnancy or current suicidal thoughts or attempts in the past month.
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: La prévention
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur actif: Usual Care
Participants will receive community referrals to treatment programs as needed and will be asked to meet research staff on a monthly basis at the clinic to provide a urine sample and fill out timeline follow-back.
R200 will be provided for sample provision.
Research staff will make referrals to treatment programs in the community as needed.
|
Participants will receive community referrals to treatment programs as needed and will be asked to meet research staff on a monthly basis at the clinic to provide a urine sample and fill out timeline follow-back.
R200 will be provided for sample provision.
Research staff will make referrals to treatment programs in the community as needed.
|
|
Expérimental: Intervention
Participants will receive text-based support on health promotion and referral content based on educational components.
Participants will be asked to meet research staff on a monthly basis at the clinic to provide a urine sample, fill out timeline follow back on self-reported alcohol and tobacco/cannabis use, and receive contingent incentives if abstinence is verified.
|
Participants will receive text-based support on health promotion and referral content based on educational components.
Participants will be asked to meet research staff on a monthly basis at the clinic to provide a urine sample, fill out timeline follow back on self-reported alcohol and tobacco/cannabis use, and receive contingent incentives if abstinence is verified.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Urinalysis results for alcohol use
Délai: From enrollment to the end of treatment at 3 months postpartum
|
An alcohol metabolite (EtG) will be measured in urine samples.
EtG can be detected in the urine up to 5 days after heavy drinking and up to 2 days after light drinking with ≥150 ng/mL for EtG as a cutoff value.
|
From enrollment to the end of treatment at 3 months postpartum
|
|
Urinalysis results for tobacco use
Délai: From enrollment to the end of treatment at 3 months postpartum
|
Biochemical verification of recent tobacco use in urine samples.
A tobacco metabolite (cotinine) will be measured in urine samples.
The metabolite can be detected up to 3-4 days after use with ≥ 80ng/mL as a cutoff.
|
From enrollment to the end of treatment at 3 months postpartum
|
|
Urinalysis results for cannabis use
Délai: From enrollment to the end of treatment at 3 months postpartum
|
Biochemical verification of recent cannabis use in urine samples.
A cannabis metabolite (THC) will be measured in urine samples.
The metabolite can be detected up to 28 days after heavy use with ≥50 ng/mL as a cutoff.
|
From enrollment to the end of treatment at 3 months postpartum
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Birth weight
Délai: Birth
|
Birth weight
|
Birth
|
|
Gestational age at birth
Délai: Birth
|
Gestational age at birth
|
Birth
|
|
Head circumference
Délai: Birth
|
Head circumference
|
Birth
|
|
Apgar score
Délai: Birth
|
Apgar score
|
Birth
|
|
NICU admission
Délai: Birth to 3 months postpartum
|
NICU admission and length of stay
|
Birth to 3 months postpartum
|
|
Infant weight at 3 months
Délai: 3 months postpartum
|
Infant weight at 3 months
|
3 months postpartum
|
|
Infant height at 3 months
Délai: 3 months postpartum
|
Infant height at 3 months
|
3 months postpartum
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude (Estimé)
1 février 2027
Achèvement primaire (Estimé)
31 janvier 2029
Achèvement de l'étude (Estimé)
30 juin 2029
Dates d'inscription aux études
Première soumission
11 septembre 2026
Première soumission répondant aux critères de contrôle qualité
14 septembre 2026
Première publication (Réel)
18 septembre 2026
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
18 septembre 2026
Dernière mise à jour soumise répondant aux critères de contrôle qualité
14 septembre 2026
Dernière vérification
1 septembre 2026
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- H26-046
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
OUI
Description du régime IPD
A limited data set in which names and other personal health identifiers are removed will be supplied to researchers on request.
The data will be made available after the publication of the study results.
Analytic files will be collected in Redcap and then prepared in SPSS, R, SAS, or STATA, with online codebooks giving the variable name, label, type, format, positions, consistency codes, and, if applicable, values and value labels.
Requesting access to data will involve drafting an abstract, checking the feasibility relative to the available data, and then seeking the permission of the principal investigator and the team for review, if appropriate.
The data sets will be ready for use and can be converted to other analytic tools.
Délai de partage IPD
After study outcomes are published for 3 years
Critères d'accès au partage IPD
those with the permission of the principal investigator and the team investigators
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
- CIF
- ANALYTIC_CODE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Non
Étudie un produit d'appareil réglementé par la FDA américaine
Non
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .